National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting, 9858-9859 [2024-02774]
Download as PDF
<![CDATA[
9858
Federal Register / Vol. 89, No. 29 / Monday, February 12, 2024 / Notices
As part of that review, the online survey
will be used to:
Measure the effect of the 2016–2017
HIPAA Audits on covered entities’ and
business associates’ subsequent actions
to comply with the HIPAA Rules.
Provide entities with an opportunity
to give feedback on the Audit and its
features, such as the helpfulness of
audit-related documents and to respond
to audit-related requests; and
Seek feedback on the effect of the
HIPAA Audit program on the entities’
day-to-day business operations.
The information, opinions, and
comments collected using the online
survey will be used to improve future
OCR HIPAA Audits.
HHS’ guidance materials and
communications, the utility of the
online submission portal, whether the
Audit helped improve entity
compliance, and the entities’ responses
to the Audit-report findings and
recommendations.
Provide OCR with information on the
burden imposed on entities to collect
ANNUALIZED BURDEN HOUR TABLE
Form name
OCR HIPAA Audit Participant Survey.
OCR HIPAA Audit Participant Survey.
Total ...........................................
1
45/60
124.5
41
1
45/60
30.75
...........................................................
207
........................
........................
155.25
[FR Doc. 2024–02737 Filed 2–9–24; 8:45 am]
National Institutes of Health
BILLING CODE 4153–01–P
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Maximizing
Investigators’ Research Award—E Study
Section, March 05, 2024, 8 a.m. to
March 6, 2024, 6 p.m., Center for
Scientific Review, RKL2, 6701
Rockledge Dr, Bethesda, MD, 20817
which was published in the Federal
Register on February 06, 2024, 89 FR
8218, Doc 2024–02265.
This meeting is being amended to
change the meeting start time from 8
a.m. to 9 a.m. The meeting is closed to
the public.
Dated: February 6, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–02775 Filed 2–9–24; 8:45 am]
BILLING CODE 4140–01–P
khammond on DSKJM1Z7X2PROD with NOTICES
Total
burden
hours
166
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
21:06 Feb 09, 2024
Average
burden per
response
Covered Entity Privacy and Security
Officer(s) or Administrators.
Business Associate Privacy and Security Officer(s) or Administrators.
Sherrette A. Funn,
Paperwork Reduction Act Reports Clearance
Officer, Office of the Secretary.
VerDate Sep<11>2014
Number of
responses per
respondent
Number of
respondents
Respondents
Jkt 262001
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Investigator Initiated
Extended Clinical Trial (R01 Clinical Trial
Required).
Date: March 8, 2024.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Rockville, MD
20892 (Video Assisted Meeting).
Contact Person: Lindsey M. Pujanandez,
Ph.D., Scientific Review Officer, Immunology
Review Branch, Scientific Review Program,
Division of Extramural Activities, National
Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers
Lane, MSC 9834, Rockville, MD 20852, (240)
627–3206, lindsey.pujanandez@nih.gov.
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 6, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–02773 Filed 2–9–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; URGenT: Translational
Efforts to Advance Gene-based Therapies for
Ultra-Rare Neurological and Neuromuscular
Disorders.
Date: February 27, 2024.
Time: 10:00 a.m. to 1:00 p.m.
E:\FR\FM\12FEN1.SGM
12FEN1
Federal Register / Vol. 89, No. 29 / Monday, February 12, 2024 / Notices
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6001
Executive Boulevard, Rockville, MD 20852.
Contact Person: Mirela Milescu, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH, HHS NSC, 6001 Executive
Blvd., Rockville, MD 20852, 301–496–5720,
mirela.milescu@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS.)
Dated: February 6, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–02774 Filed 2–9–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Extension and Modification of the
National Customs Automation
Program Test Concerning the
Submission Through the Automated
Commercial Environment of Certain
Unique Entity Identifiers for the Global
Business Identifier Evaluative Proof of
Concept
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: General notice.
AGENCY:
On July 21, 2023, U.S.
Customs and Border Protection (CBP)
published a notice in the Federal
Register extending and modifying a
National Customs Automation Program
Test concerning the submission of
unique entity identifiers for the Global
Business Identifier (GBI) Evaluative
Proof of Concept (EPoC). This document
republishes and supersedes the notice
published on July 21, 2023, announces
an extension of the test period through
February 23, 2027, notes a clarification
in the purpose and scope of the GBI
EPoC, and removes commodity and
country of origin limitations on the
entries eligible for the test. In addition,
this document makes changes to the
contact information for questions
regarding the test, provides new web
addresses dedicated to obtaining GBIs,
and makes minor technical changes.
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
21:06 Feb 09, 2024
Jkt 262001
The GBI EPoC commenced on
December 19, 2022, and will continue
through February 23, 2027, subject to
any extension, modification, or early
termination as announced in the
Federal Register. CBP began to accept
requests from importers of record and
licensed customs brokers to participate
in the test on December 2, 2022, and
CBP will continue to accept such
requests until the GBI EPoC concludes.
Public comments on the test are invited
and may be submitted to the address set
forth below, at any time during the test
period.
FOR FURTHER INFORMATION CONTACT: For
policy-related questions, contact Garrett
Wright, Director, Trade Modernization
Division, Trade Policy and Programs
Directorate, Office of Trade, U.S.
Customs and Border Protection, at (202)
897–9877 or via email at GBI@
cbp.dhs.gov, with a subject line reading
‘‘Global Business Identifier Test-GBI.’’
For technical questions related to the
Automated Commercial Environment
(ACE) or Automated Broker Interface
(ABI) transmissions, software vendors,
importers of record, and licensed
customs brokers should contact their
assigned ACE or ABI client
representatives, respectively. Interested
parties without an assigned client
representative should direct their
questions to Steven Zaccaro, Client
Services Division, Office of Trade, U.S.
Customs and Border Protection, at (571)
358–7809 or via email at
clientrepoutreach@cbp.dhs.gov.
SUPPLEMENTARY INFORMATION: On
December 2, 2022, U.S. Customs and
Border Protection (CBP) published a
General Notice (the December 2 Notice)
in the Federal Register (87 FR 74157)
announcing a National Customs
Automation Program (NCAP) Test
concerning the submission through the
Automated Commercial Environment
(ACE) of certain unique entity
identifiers for the Global Business
Identifier (GBI) Evaluative Proof of
Concept (EPoC). On July 21, 2023, CBP
published a General Notice (the July 21
Notice) in the Federal Register (88 FR
47154) extending and modifying the
December 2 Notice. Specifically, the
July 21 Notice extended the test period
from July 21, 2023, through February 14,
2024; provided the correct web address
for interested parties to use to obtain the
Legal Entity Identifier (LEI) from the
Global Legal Entity Identifier
Foundation (GLEIF); and clarified that
CBP would allow participants to
provide one or more of the three
identifiers for the manufacturers,
shippers, and sellers (and optionally,
exporters, distributors, and packagers)
DATES:
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
9859
of merchandise, and that CBP would not
require transmission of all three
identifiers to participate in the test. This
document republishes and supersedes
the July 21 Notice, with the following
modifications.
First, the test period has been
extended from February 14, 2024,
through February 23, 2027. Second, CBP
made changes to Sections I.B. (Global
Business Identifier Evaluative Proof of
Concept (GBI EPoC)) and VI. (Evaluation
Criteria) to clarify the purpose and
scope of the test. CBP will continue to
assess the functionality and
effectiveness of universal global
business identifiers to address data gaps
caused by the unreliability of the
manufacturer or shipper identification
code (MID), in addition to exploring
opportunities to enhance supply chain
traceability and visibility more
broadly—including examining how
CBP, Partner Government Agencies
(PGAs), and the trade industry might
leverage GBIs to comply with growing
supply chain traceability requirements.
Third, CBP has expanded the GBI
EPoC to include entries of merchandise
classifiable in any subheading of the
Harmonized Tariff Schedule of the
United States (HTSUS) and entries of
imported merchandise from any country
of origin. When CBP initially launched
the GBI EPoC, the test was limited to
entries of merchandise in five (5)
categories (alcohol, toys, seafood,
personal items, and medical devices),
and to merchandise with 10 countries of
origin (Australia, Canada, China,
France, Italy, Mexico, New Zealand,
Singapore, United Kingdom, and
Vietnam). These requirements
significantly limited the range of entries
that could be evaluated under the test.
As a result, CBP is removing these test
limitations. It is important to note that
the test continues to be limited to type
01 (formal) and type 11 (informal)
entries.
Fourth, as noted in the FOR FURTHER
INFORMATION CONTACT section above, the
office responsible for the GBI EPoC has
changed (it is no longer the Interagency
Collaboration Division, Trade Policy
and Programs Directorate, Office of
Trade, but is now the Trade
Modernization Division, Trade Policy
and Programs Directorate, Office of
Trade), and the point of contact for
interested parties without an assigned
client representative who have technical
questions has changed. Fifth, GS1 and
Dun & Bradstreet have created specific
web pages dedicated to the GBI EPoC for
obtaining a GBI; Section III.A.
(Obtaining Global Business Identifier
(GBI) Numbers) has been updated to
include the new web addresses for the
E:\FR\FM\12FEN1.SGM
12FEN1
]]>Agencies
[Federal Register Volume 89, Number 29 (Monday, February 12, 2024)]
[Notices]
[Pages 9858-9859]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-02774]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice
of Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; URGenT: Translational Efforts to
Advance Gene-based Therapies for Ultra-Rare Neurological and
Neuromuscular Disorders.
Date: February 27, 2024.
Time: 10:00 a.m. to 1:00 p.m.
[[Page 9859]]
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6001 Executive Boulevard,
Rockville, MD 20852.
Contact Person: Mirela Milescu, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural
Activities, NINDS/NIH, HHS NSC, 6001 Executive Blvd., Rockville, MD
20852, 301-496-5720, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.853,
Clinical Research Related to Neurological Disorders; 93.854,
Biological Basis Research in the Neurosciences, National Institutes
of Health, HHS.)
Dated: February 6, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-02774 Filed 2-9-24; 8:45 am]
BILLING CODE 4140-01-P
